<DOC>
	<DOCNO>NCT00752076</DOCNO>
	<brief_summary>1 . Detection EGFR mutation cancer cell malignant pleural effusion . 2 . Established cancer cell line without EGFR mutation malignant pleural effusion .</brief_summary>
	<brief_title>Detection EGFR Mutation Malignant Pleural Effusion Lung Cancer Patients Cancer Cell Lines Establishment</brief_title>
	<detailed_description>Lung cancer lead cause mortality world . Previous study show 88 % lung cancer case belong non-small cell lung cancer ( NSCLC ) Taiwan ( 1 ) . Approximately 50~90 % NSCLC patient expression ( described overexpression ) EGFR cancer ( 2,3 ) . Although target EGFR kinase domain use inhibitor gefitinib ( Iressa ) erlotinib ( Tarceva ) effect solid tumor , achieves impressive response subgroup NSCLC especially Asian ethnic background , female sex , absence history smoking , tumor histologic feature adenocarcinoma ( 3,4,5 ) . Molecular study highly responsive case reveal high percentage somatic mutation within tyrosine kinase , ATP-binding domain EGFR gene ( 6 ) . One possible explanation phenomenon cancer cell `` addict '' signal via mutant EGFRs die mutant oncoprotein inactivate ( 7 ) . However , specific mechanism underlie epidermal growth factor tyrosine kinase inhibitor ( EGFR-TKI ) induce cell death well delineate ( 7 ) . Approximately 90 % mutation affect specific amino acid . In-frame deletion exon 19 centered codon 756 750 make 45~50 % mutation , another 35~45 % consist missense mutation leucine arginine codon 858 ( L858R ) exon 21 ( 8 , 9 , 10 ) . The link EGFR-TKI response EGFR mutation confirm , increase prevalence mutation Asian ( 25 % 50 % ) compare North American Western European patient ( 10 % ) currently unexplained ( 6,8-12 ) . The response rate TKI treatment mutations-positive 77 % ( 30 % 100 % series &gt; 60 % ) compare 10 % mutation-negative case ( 6 ) . It interest exon 19 deletion increase response survival TKIs compare L858R case ( 10 , 13 , 14 ) . This contrast natural history patient , exon 19 deletion appear short survival L858R ( 8 ) . The biological difference still unknown different mutation may different biochemical signaling property ( 15 ) . In study , collect pleural effusion lung cancer patient . We characterize EGFR status cancer cell malignant pleural effusion try establish cancer cell line patient . We hope establish several cell line different mutation compare difference response signal pathway cell line . We also explore detailed mechanism TKI responsive cancer cell try develop agent enhance pathway .</detailed_description>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<criteria>All malignant pleural effusion relate NSCLC April 2008 March 2009 . Older 18 year old . The patient receive thoracentesis The patient compatible inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>EGFR mutation</keyword>
	<keyword>NSCLC cell line</keyword>
	<keyword>Malignant pleural effusion</keyword>
</DOC>